AVAPS-AE Efficacy Study
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | July 2011 |
| End Date: | May 2015 |
Randomized Controlled Trial Evaluating the Feasibility of AVAPS-AE vs. CPAP vs.Bilevel Pressure Support Ventilation in Obesity Hypoventilation Syndrome
The purpose of this study is to evaluate the feasibility of using of the Average Volume
Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP)
and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed
with Obesity Hypoventilation syndrome.
The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will
yield daytime gas exchange values which are equivalent or no worse when compared to using
CPAP and bilevel PSV modes of ventilation in the OHS population.
Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP)
and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed
with Obesity Hypoventilation syndrome.
The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will
yield daytime gas exchange values which are equivalent or no worse when compared to using
CPAP and bilevel PSV modes of ventilation in the OHS population.
Inclusion Criteria:
- Age greater than or equal to 18 years of age; less than or equal to 70 years of age
- Diagnosis of Obesity Hypoventilation Syndrome via a diagnostic sleep study in the
past 3 months but have not initiated therapy
- BMI greater than or equal to 30 kg/m2
- Daytime PaCO2 greater than or equal to 45mmHg
- AHI > 5
- Daytime pH > 7.35
- FEV1/FVC > 70%
Exclusion Criteria:
- Acutely ill, medically complicated or who are medically stable, or as otherwise
determined by the investigator
- Respiratory alkalosis (pH > 7.45), per investigator discretion
- Emergency admissions on chronic respiratory failure
- Hospitalization for respiratory exacerbation < 6 weeks prior to screening visit
- Participants in whom PAP therapy is otherwise medically contraindicated
- Impaired upper airway function. For example, obstruction due to
infections(laryngitis, epiglottis), craniofacial malformations, tumors,
uvulopalatopharyngoplasty, presence of tracheostomy, or bilateral vocal cord palsy
that does not allow tolerance of NPPV
- Facial trauma, burns, surgery or anatomical abnormalities interfering with mask fit.
We found this trial at
2
sites
Click here to add this to my saved trials
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials